We are thrilled to share the success of our Management Empowerment Program (MEP), exclusively designed for our Area Business Managers (ABMs) from the South and North Zones in November 2024.

This transformative initiative aimed to elevate capabilities and empower our ABMs to lead with greater impact in today’s dynamic market landscape.

Key Focus Areas were Data Analytical Capabilities, Advanced Selling, Coaching Skills, Team Development & Leadership, and Driving Business Excellence.

This robust program witnessed the enthusiastic participation of 250 ABMs, with a stellar Net Promoter Score of 90.

Our participants had the privilege of receiving guidance from Mr. P K Guha (MD & CEO, Zuventus).

The sessions were expertly facilitated by - Mr. Jayant Khanzode (GM-HR, Zuventus), Dr. Amrit Karmarkar (Senior Manager - HR), Mr. Prashant Menon (Founder & Director, Workplace Dynamics), and Dr. Shriharsh Kaushik (Founder, Krux EM Consultancy)

Together, we continue to build future-ready leaders, equipped with the skills to navigate challenges and seize opportunities with confidence and excellence.

We are excited to announce the success of Fulcrum - Managerial Development Program, exclusively crafted for our Regional Business Managers (RBMs) from the West and East Zones. This program was designed to enhance essential managerial competencies and equip our RBMs to lead with greater impact in today’s dynamic market landscape.

Key Focus Areas were Change Management, Building High-Performing Teams, Coaching and Mentoring, Customer Relationship Management, Managing Team Conflicts, and Problem Solving and Decision Making

This impactful program saw the enthusiastic participation of 100+ RBMs, earning a remarkable Net Promoter Score of 90.

Our participants had the privilege of receiving guidance from Mr. P K Guha (MD & CEO, Zuventus).

The sessions were expertly facilitated by Mr. Anil Nagpal (MD & Chairman, Argyle HR Solutions), ensuring the delivery of cutting-edge learning.

A special acknowledgment to our Human Resources team, Mr. Jayant Khanzode and Dr. Amrit Karmarkar, for their exceptional efforts in designing and delivering this transformative program.

Together, we continue to empower our leaders to drive excellence, foster innovation, and lead with confidence in an ever-evolving marketplace.

Aim and background: To assess the efficacy and safety of Ibutilide infusion for cardioversion of atrial fibrillation (AF) or flutter (AFL) to sinus rhythm. Materials and methods: This open-label, multicenter phase IV study was conducted at six sites across India. The study enrolled 120 patients (108 with AF, 12 with AFL), each receiving up to two, 10-minute intravenous doses of 1.0 mg Ibutilide. The primary endpoints were the proportion of patients achieving cardioversion and the mean time taken to achieve cardioversion. Secondary endpoints included the proportion of patients maintaining sinus rhythm at 24 hours and the incidence of adverse events.

Results: The cardioversion rate at 4 hours post-Ibutilide infusion among 120 patients was 65.83% (n = 79), with an average conversion time of 35.12 ± 36.71 minutes. At 24 hours, 85 patients (70.8%) had successful cardioversion, with a mean time of 107.24 minutes. The majority of patients (71.76%) had achieved cardioversion within 30 minutes. Of the 85 patients who achieved successful conversion, 82 (68.3%) maintained sinus rhythm at 24 hours. A total of 66 patients (55%) achieved cardioversion with the first bolus whereas 19 (15.8%) needed a second bolus. Atrial fibrillation patients had a higher conversion rate (75%) compared to AFL patients (33%). A total of 10 adverse events were recorded in eight patients (6.67%), including nausea, headache, palpitations, and bradycardia. Three severe cardiac events, one case of ventricular tachycardia, and two of tachycardia necessitated discontinuation of Ibutilide. No fatalities or serious adverse events (SAE) were reported.

Conclusion: Ibutilide was found to be effective and well-tolerated for rapid restoration of sinus rhythm in patients with AF or AFL.

Clinical Trial Registry of India: CTRI/2018/01/011248.

Keywords: Atrial fibrillation, Atrial flutter, Cardioversion, Ibutilide

Zuventus Healthcare Limited, Mumbai was voted in a Nation wide Poll conducted by Network 7 Research as India’s Most Respected Pharmaceutical Company by Medical Professionals 2024 at the 16th Annual Pharma Leaders Healthcare Super Brand Awards 2024 on Friday at Hilton Mumbai International Airport. Padma Shri Dr Mukesh Batra, Founder Chairman Emeritus, Dr Batra’s Healthcare presented the prestigious Award Trophy & Certificate of Excellence in the presence of Dr Satya Brahma, Founder & Editor-In-Chief of Network 7 Media Group.